Exonate
Exonate develops and licenses Vascular Endothelial Growth Factors (VEGF) control agents that may be used as therapeutics in areas such as pain control, macular degeneration and cancer.

Profile
Exonate’s research in this area has identified therapeutic candidates for wet Age Related Macular Degeneration that can be administered as a simple eye drop, thereby over-coming the unpleasant need for monthly injections in the eye.
Competing injectable anti-VEGFdirected therapy currently constitutes the gold-standard treatment for wet Age Related Macular Degeneration (wAMD) and other neovascular diseases of the eye.
News and press releases
Neupulse raises £918k in a second round of funding
- 20th January 2023 1:05 pm·
SurePulse and partners land £1.4m Innovate UK award
- 2nd November 2022 1:37 pm·
PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test
- 27th October 2022 11:40 am·
Nottingham trio share award for brain imaging innovation
- 27th October 2022 11:28 am·
Face and voice recognition technology set to transform diagnosis of perinatal depression
- 20th October 2022 4:01 pm·
BlueSkeye AI wins ‘One to Watch’ Award at Medilink Business Awards 2022
- 2nd February 2022 12:22 pm·
Data privacy startup ID Ward raises €1.1 million to launch its decentralised advertising technology
- 2nd February 2022 11:53 am·
NuVision Biotherapies announces the appointment of its new Chief Executive Officer and Chief Operating Officer
- 13th January 2022 11:43 am·
BlueSkeye AI shortlisted as a finalist for the Medilink Midlands Business Awards 2022
- 17th December 2021 12:40 pm·
University spin-out named best medtech start-up
- 29th November 2021 2:47 pm·
Green jobs at Cheesecake Energy
- 1st November 2021 4:07 pm·
Steve Cliffe joins BlueSkeye AI as it scales the development of its technology and customer portfolio
- 26th October 2021 9:36 am·
Cheesecake Energy announces new board appointments
- 5th October 2021 4:05 pm·
@ExonateUK on Twitter
Your story has the power to ignite the spark and bring change to #womenshealth. With #XProject, we are determined to bring your voice to the forefront. Join us on our journey to close the gaps in women’s #health 👉 https://go.roche.com/XProject_SubmissionHub #MyStoryforChange #Healthcare
#HappyLunarNewYear! Janssen wishes all of our patients, care partners and healthcare professionals a happy and healthy New Year!
Nearly 50% of UK lung cancer patients wait, on average, over 2 months for treatment.
To help address this, we announce our initiative to support the NHS: PATHFINDER – an innovative optimisation project to improve pathways for lung cancer patients. #LungCancerAwarenessMonth
Science Club continues with Kidney dissection, the year 7s learnt how the structure of the kidney relates to its function #STEM #STEMeducation #STEM
❄️ With freezing temperatures across many parts of the UK this week, it's especially important to keep yourself warm if you live with #diabetes.
A thread 👇 (1/4)
We’re continuing to innovate and strengthen our understanding of the #Science of #BloodCancer to advance new treatment options for patients. Learn more about our efforts in chronic lymphocytic #Leukemia at #ASH22. #CLL
#GeographicAtrophy (GA), a disease currently without an approved treatment, affects over five million people globally.
We’re advancing potential GA treatments with the goal to reduce patient burden and preserve sight.
Learn more: https://bit.ly/3EXyj4q
#JanssenRetina
Women’s health has been traditionally underfunded. @SpringboardEnt with CEO Natalie Buford Young have made it their mission to close the gaps in funding for women’s health. Tune in to our podcast to learn more. #XProject
http://go.roche.com/business-case-wh